attention deficit hyperactivity disorder (adhd)

Guanfacine hydrochloride (Intuniv) 是一种 α2A 肾上腺素受体激动剂，Kd=31 nM，具有抗高血压作用。

Bavisant (JNJ-31001074) 是一种特异性和口服活性的人 H3 受体拮抗剂。 Bavisant 可用于作用机制的研究，包括觉醒和认知以及 ADHD 的治疗。

Sofiniclin (ABT 894) is an agonist of nicotinic acetylcholine receptor (nAChR). It is used for the research for attention-deficit hyperactivity disorder (ADHD).

GSK3-IN-9 (0713) 是一种选择性抑制糖原合成酶激酶3 (GSK3) 的化合物。GSK3-IN-9 在脆性X综合征、注意缺陷多动障碍 (ADHD)、儿童癫痫、智力残疾、糖尿病、急性髓性白血病 (AML)、自闭症以及精神障碍等疾病的研究中具有潜在应用。

Edivoxetine( LY2216684) is a selective norepinephrine reuptake inhibitor being developed as a treatment for attention deficit hyperactivity disorder (ADHD) and antidepressants.

Guanfacine-13C,15N3is intended for us as an internal standard for the quantification of guanfacine by GC- or LC-MS. Guanfacine is an α2-adrenergic receptor (α2-AR) agonist with Kivalues of 93, 1,380, and 3,890 nM for α2A-, α2B-, and α2C-ARs, respectively, in a radioligand binding assay.1It has EC50values of 52, 288, and 602 nM for α2A-, α2B-, and α2C-ARs, respectively, for stimulated [35S]GTPγS binding. It also binds to imidazoline receptor 1 (Ki= 19 nM in a radioligand binding assay).2Guanfacine (0.3-5 mg kg) binds to adrenergic receptors in the central nervous system and lowers blood pressure in hypertensive rats in a dose-dependent manner.3It also improves spatial working memory deficits induced by hypobaric hypoxia in rats.4Formulations containing guanfacine are used in the treatment of high blood pressure and attention deficit hyperactivity disorder (ADHD). 1.Jasper, J.R., Lesnick, J.D., Chang, L.K., et al.Ligand efficacy and potency at recombinant α2 adrenergic receptors: Agonist-mediated [35S]GTPγS bindingBiochem. Pharmacol.55(7)1035-1043(1998) 2.Nikolic, K., Filipic, S., and Agbaba, D.QSAR study of imidazoline antihypertensive drugsBioorg. Med. Chem.16(15)7134-7140(2008) 3.Scholtysik, G.Pharmacology of guanfacineBr. J. Clin. Pharmacol.10(Suppl 1)21S-24S(1980) 4.Kauser, H., Sahu, S., Kumar, S., et al.Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive declineNeuroscience254110-119(2013)

CX 717 是 AMPA 受体的正变构调节剂，具有抗抑郁样作用。CX 717 可用于成人注意力缺陷多动障碍（ADHD）的研究。

Droxidopa (L-DOPS) hydrochloride 是一种有效的、具有口服活性的去甲肾上腺素前体。Droxidopa hydrochloride 可增加站立血压，改善直立性低血压症状并提高站立能力。Droxidopa hydrochloride 具有研究神经源性直立性低血压（nOH）和替代性多动症 (注意缺陷多动障碍) 的潜力[3]。

Sofinicline benzenesulfonate (ABT 894 benzenesulfonate) 为一种针对nAChR的α4β2亚型具有高选择性的烟碱型乙酰胆碱受体激动剂（IC50=0.1 nM）。该化合物展现了调节认知功能的能力，尤其是在改进注意力、记忆以及工作记忆方面。此外，Sofinicline benzenesulfonate 在对抗注意力缺陷及多动障碍（ADHD）的研究领域中具有重要应用价值。